Skip to main content
. 2017 Mar 23;8(20):33353–33364. doi: 10.18632/oncotarget.16495

Figure 6. Silencing Arp2 impaired the tumorigenicity of CD133+ U87-MG neurosphere cells in vivo.

Figure 6

Different amount of cells (2×103, 1×104, 5×104) were implanted into the brain of nude mice. (A) Image of the formed xenografts at 42 days after implantation. (B) ShArp2 decreased the incidences of tumor formation in intracranial xenograft models.